Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 37.9% during trading on Thursday . The stock traded as high as C$0.24 and last traded at C$0.20. 1,160,600 shares changed hands during trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The company has a market capitalization of C$20.91 million, a PE ratio of -12.00 and a beta of 0.20. The business has a fifty day moving average price of C$0.09 and a 200 day moving average price of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Why Are These Companies Considered Blue Chips?
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- What is a SEC Filing?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- The 3 Best Blue-Chip Stocks to Buy Now
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
